NVIDIA, AI & Quantum Leaders Drive Health Tech: 2 Stocks to Buy

The AI in healthcare market is projected for explosive growth, expanding from $39.25 billion in 2025 to over $500 billion by 2032, driven by AI-enabled diagnostics, drug discovery, and clinical automation. Major players like NVIDIA and Palantir, along with quantum computing firms, are aggressively investing in this sector. Among specialized MedTech companies, Butterfly Network (BFLY) is leveraging AI/ML for diagnostic imaging with strong projected 2025 earnings growth, while Omnicell (OMCL) is innovating medication management with AI and robotics, presenting a compelling valuation relative to its industry despite solid 2026 earnings growth forecasts.

Analysis

The artificial intelligence (AI) in healthcare market is positioned for significant secular growth, with projections indicating a compound annual growth rate (CAGR) of 44.0% from 2025 to 2032, expanding the market from $39.25 billion to over $500 billion. This trend is being validated by aggressive strategic moves from major technology firms like NVIDIA, Palantir, and IBM, who are deploying their AI and quantum computing platforms to enhance diagnostics, drug discovery, and clinical workflows. Within this ecosystem, two specialized MedTech companies are highlighted as attractive opportunities. Butterfly Network (BFLY) is demonstrating traction in AI-driven diagnostic imaging, with its handheld ultrasound achieving a high accuracy rate (AUROC of 0.94) in detecting aortic stenosis. The company's fundamentals appear strong, with projected 2025 earnings growth of 29.4% on a 10.9% revenue increase, and its stock has recently outperformed its industry with a 7.9% gain in the last 30 days. Concurrently, Omnicell (OMCL) is focusing on automating medication management through new AI and robotics-based product lines like MedTrack and MedVision. While its projected 2026 revenue growth is more modest at 2.3%, its earnings are forecast to grow 12.9%. The primary investment thesis for OMCL is its valuation; it trades at a forward 12-month price-to-sales (P/S) multiple of 1.25, a significant discount to both its five-year median of 13.9X and the industry average.

Key Decisions for Investors

• Investors should consider allocating capital to the AI in healthcare theme, as the sector's explosive 44% projected CAGR is being actively validated by strategic investments from major technology and quantum computing firms.
• For growth-oriented portfolios, Butterfly Network (BFLY) warrants consideration due to its demonstrated product innovation in AI diagnostics, strong projected 2025 earnings growth of 29.4%, and positive share price momentum.
• Value-focused investors should evaluate Omnicell (OMCL), as its forward P/S multiple of 1.25 represents a substantial discount to historical and industry norms, potentially offering a favorable entry point if the company successfully executes on its technology roadmap and delivers its projected 12.9% earnings growth for 2026.